Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
{{output}}
Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing-remitting multiple sclerosis (RRMS). B and T cells may exert multiple pro-inflammatory... ...
